[특허]Compositions and methods for therapeutic delivery with frozen particles

The Invention Science Fund I, LLC

검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
검색연산자

검색도움말
검색연산자	기능	검색시 예
()	우선순위가 가장 높은 연산자	예1) (나노 (기계 \| machine))
공백	두 개의 검색어(식)을 모두 포함하고 있는 문서 검색	예1) (나노 기계) 예2) 나노 장영실
\|	두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색	예1) (줄기세포 \| 면역) 예2) 줄기세포 \| 장영실
!	NOT 이후에 있는 검색어가 포함된 문서는 제외	예1) (황금 !백금) 예2) !image
*	검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색	예) semi*
""	따옴표 내의 구문과 완전히 일치하는 문서만 검색	예) "Transform and Quantization"

과학기술 지식인프라 ScienceON

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

특허 상세정보

MyON담기

내보내기 페이스북 공유 트위터 공유 카카오톡 공유

Compositions and methods for therapeutic delivery with frozen particles

특허상세정보
국가/구분	United States(US) Patent 등록
국제특허분류(IPC7판)	G06F-019/00 A61M-005/30 A61M-037/00 G06Q-050/22 A61K-009/14 G06F-019/18
미국특허분류(USC)	702/019; 604/065; 604/068
출원번호	US-0290690 (2008-10-31)
등록번호	US-8793075 (2014-07-29)
발명자 / 주소	Boyden, Edward S. Hyde, Roderick A. Leuthardt, Eric C. Myhrvold, Nathan P. Sweeney, Elizabeth A. Wood, Jr., Lowell L.
출원인 / 주소	The Invention Science Fund I, LLC
인용정보	피인용 횟수 : 1 인용 특허 : 173

초록

Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.

대표
청구항
▼

1. A method, comprising: administering at least one solid frozen particle therapeutic composition including at least one tracer agent at high speed to at least one subject, and with use of at least one computing device, comparing information regarding at least one aspect of administering the at least one solid frozen particle therapeutic composition to the at least one subject based on the real-time feedback signal from the at least one tracer agent, and information regarding at least one clinical outcome following receipt by the at least one subject of at least one solid frozen particle therapeutic composition; andproviding output information regarding at least one aspect of the administering the at least one solid frozen particle therapeutic composition to the at least one subject based on the real-time feedback signal from the at least one tracer agent;wherein the output information is in the form of at least one of a code indicative of at least one vaccination delivered, a code indicative of at least one therapeutic agent delivered, a code indicative of at least one diagnostic agent delivered, a code indicative of at least one interaction of a delivered agent and at least one biological or chemical agent in the subject, a code indicative of at least one detection material delivered, a code indicative of the depth of penetration of a delivered agent, or a code indicative of the condition of at least one location of an administered frozen particle composition. 2. The method of claim 1, further including determining at least one statistical correlation. 3. The method of claim 1, further including counting the occurrence of at least one clinical outcome. 4. The method of claim 1, further including comparing information regarding at least one aspect of administering the at least one solid frozen particle therapeutic composition and the information regarding at least one clinical outcome based on the real-time feedback signal from the at least one tracer agent, before the administration of the at least one solid frozen particle therapeutic composition to another subject. 5. The method of claim 1, wherein the information regarding the at least one aspect of administering the at least one solid frozen particle therapeutic composition includes information regarding the amount of at least one solid frozen particle therapeutic composition or therapeutic agent administered to at least one biological tissue of a subject based on the real-time feedback signal from the at least one tracer agent. 6. The method of claim 1, wherein the information regarding the at least one aspect of administering the at least one solid frozen particle therapeutic composition includes information regarding at least one dimension of biological tissue penetration based on the real-time feedback signal from the at least one tracer agent. 7. The method of claim 6, wherein the information regarding the at least one dimension of biological tissue penetration includes information regarding at least one of depth, width, or breadth of administration of the at least one solid frozen particle therapeutic composition to the at least one biological tissue of at least one subject based on the real-time feedback signal from the at least one tracer agent. 8. The method of claim 1, wherein the information regarding at least one aspect of administering the at least one solid frozen particle therapeutic composition includes information regarding two or more subjects with one or more common attributes. 9. The method of claim 8, wherein the one or more common attributes include genetic attributes, mental attributes, or psychological attributes. 10. The method of claim 8, wherein the one or more common attributes include genotype attributes or phenotype attributes. 11. The method of claim 10, wherein the one or more common attributes include at least one of height; weight; medical diagnosis; familial background; results on one or more medical tests; ethnic background; body mass index; age; presence or absence of at least one disease or condition; species; ethnicity; race; allergies; gender; thickness of epidermis; thickness of dermis; thickness of stratum corneum; keratin deposition; collagen deposition; blood vessel condition; skin condition; hair or fur condition; muscle condition; tissue condition; organ condition; nerve condition; brain condition; presence or absence of at least one biological, chemical, or therapeutic agent in the subject; pregnancy status; lactation status; genetic profile; proteomic profile; partial or whole genetic sequence; partial or whole proteomic sequence; medical history; or blood condition. 12. The method of claim 1, wherein the output information includes at least one of a response signal, a comparison code, a comparison plot, a diagnostic code, a treatment code, a test code, a code indicative of at least one treatment received, a code indicative of at least one prescribed treatment step, a code indicative of at least one vaccination administered; a code indicative of at least one therapeutic agent administered; a code indicative of at least one diagnostic agent administered; a code indicative of at least one interaction of a administered agent and at least one biological or chemical agent in the subject; a code indicative of at least one dispersion or location of at least one administered agent; a code indicative of at least one detection material administered; a code indicative of the depth of penetration of an administered agent; or a code indicative of the condition of at least one location of an administered solid frozen particle composition. 13. The method of claim 1, wherein the information regarding at least one aspect of administering the at least one solid frozen particle therapeutic composition includes information regarding at least one cellular or tissue source. 14. The method of claim 13, wherein the information regarding at least one cellular or tissue source includes information regarding at least one abnormal cellular or tissue source. 15. The method of claim 13, wherein the information regarding at least one cellular or tissue source includes information regarding at least one type of cell or tissue. 16. The method of claim 1, wherein the at least one solid frozen particle therapeutic composition includes at least one of nitrogen, carbon dioxide, hydrogen oxide, helium, neon, xenon, krypton, air, oxygen, chlorine, bromine, argon, polyethylene glycol, acetone, ethyl acetate, dimethyl sulfoxide, dimethyl formamide, dioxane, hexamethylphosphorotriamide, perfluorohydrocarbon, methanol, ethanol, tert-butyl alcohol, formic acid, hydrogen fluoride, ammonia, acetic acid, benzene, carbon tetrachloride, acetonitrile, hexane, methylene chloride, carboxylic acid, saline, Ringer's solution, lactated Ringer's solution, Hartmann's solution, acetated Ringer's solution, phosphate buffered solution, TRIS-buffered saline solution, Hank's balanced salt solution, Earle's balanced salt solution, standard saline citrate, HEPES-buffered saline, dextrose, glucose, or diethyl ether. 17. The method of claim 1, wherein the at least one solid frozen particle composition includes at least one major dimension of approximately one centimeter or less, approximately one millimeter or less, approximately one micrometer or less, approximately one nanometer or less, or any value therebetween. 18. The method of claim 1, wherein the at least one solid frozen particle therapeutic composition includes one or more reinforcement agents. 19. The method of claim 1, wherein the at least one solid frozen particle therapeutic composition includes one or more explosive materials. 20. The method of claim 1, wherein the receipt by the at least one subject of the at least one solid frozen particle therapeutic composition is pursuant to at least one clinical trial. 21. The method of claim 1, further including creating at least one inclusion criterion and at least one exclusion criterion for a clinical trial involving the at least one solid frozen particle therapeutic composition. 22. The method of claim 1, wherein comparing the information further includes suggesting the inclusion of one or more of the at least one subject in at least one clinical trial. 23. The method of claim 1, wherein comparing the information further includes suggesting the exclusion of one or more of the at least one subject in at least one clinical trial. 24. The method of claim 1, further including using one or more comparisons to predict at least one clinical outcome regarding at least one second subject. 25. The method of claim 24, wherein the at least one second subject has not received the at least one solid frozen particle therapeutic composition. 26. The method of claim 24, further including predicting at least one clinical outcome involving the at least one second subject, wherein the at least one second subject is a plurality of people; and segregating subject identifiers associated with the plurality of people in reference to the predicted at least one clinical outcome. 27. The method of claim 24, further including determining the eligibility of the at least one second subject for at least one clinical trial. 28. A method of predicting a clinical outcome of administering at least one solid frozen particle therapeutic composition to at least one biological tissue of at least one first subject, comprising: administering at high speed at least one solid frozen particle therapeutic composition including at least one tracer agent, to at least one biological tissue of at least one first subject and to at least one biological tissue of at least one second subject, and with the use of at least one computing device, determining a similarity or a dissimilarity in information regarding at least one aspect of administering the at least one solid frozen particle therapeutic composition to the at least one biological tissue of the at least one first subject to information regarding at least one aspect of administering at least one solid frozen particle therapeutic composition to the at least one biological tissue of the at least one second subject based on real-time feedback of the detected at least one tracer agent, wherein the at least one second subject attained a clinical outcome following receipt of the at least one solid frozen particle therapeutic composition; andproviding output information regarding at least one aspect of the administering the at least one solid frozen particle therapeutic composition to the at least one biological tissue of at least one subject based on the real-time feedback signal from the at least one tracer agent. 29. The method of claim 28, wherein the information regarding at least one aspect of administering the at least one solid frozen particle therapeutic composition includes information regarding amount of at least one solid frozen particle therapeutic composition or therapeutic agent administered to at least one biological tissue of at least one subject based on the real-time feedback signal from the at least one tracer agent. 30. The method of claim 28, wherein the output information is based on the determination. 31. The method of claim 28, wherein the information regarding at least one aspect of administering the at least one solid frozen particle therapeutic composition includes information regarding at least one dimension of biological tissue penetration based on the real-time feedback signal from the at least one tracer agent. 32. The method of claim 31, wherein the information regarding at least one dimension of biological tissue penetration includes information regarding at least one of depth, width, or breadth of administration of at least one solid frozen particle therapeutic composition to at least one biological tissue of at least one subject based on the real-time feedback signal from the at least one tracer agent. 33. The method of claim 28, wherein the information regarding at least one aspect of administering the at least one solid frozen particle therapeutic composition includes information regarding two or more subjects with one or more common attributes. 34. The method of claim 33, wherein the one or more common attributes include genetic attributes, mental attributes, or psychological attributes. 35. The method of claim 33, wherein the one or more common attributes include genotype attributes or phenotype attributes. 36. The method of claim 35, wherein the one or more common attributes include at least one of height; weight; medical diagnosis; familial background; medical history; results on one or more medical tests; ethnic background; body mass index; age; presence or absence of at least one disease or condition; species; ethnicity; race; allergies; gender; thickness of epidermis; thickness of dermis; thickness of stratum corneum; keratin deposition; collagen deposition; lymph condition; blood vessel condition; skin condition; hair or fur condition; muscle condition; tissue condition; organ condition; nerve condition; brain condition; presence or absence of at least one biological, chemical, or therapeutic agent in the subject; pregnancy status; lactation status; genetic profile; proteomic profile; partial or whole genetic sequence; partial or whole proteomic sequence; or blood condition. 37. The method of claim 28, wherein the output information includes at least one of a response signal, a comparison code, a comparison plot, a diagnostic code, a treatment code, a test code, a code indicative of at least one treatment received, a code indicative of at least one prescribed treatment step, a code indicative of at least one vaccination administered; a code indicative of at least one therapeutic agent administered; a code indicative of at least one diagnostic agent administered; a code indicative of at least one interaction of a administered agent and at least one biological or chemical agent in the subject; a code indicative of at least one dispersion or location of at least one administered agent; a code indicative of at least one detection material administered; a code indicative of the depth of penetration of an administered agent; or a code indicative of the condition of at least one location of an administered solid frozen particle therapeutic composition. 38. The method of claim 28, wherein the information regarding at least one aspect of administering at least one solid frozen particle therapeutic composition includes information regarding at least one cellular or tissue source. 39. The method of claim 38, wherein the information regarding at least one cellular or tissue source includes information regarding at least one abnormal cellular or tissue source. 40. The method of claim 38, wherein the information regarding at least one cellular or tissue source includes information regarding at least one type of cell or tissue. 41. The method of claim 28, wherein the at least one solid frozen particle therapeutic composition includes at least one of nitrogen, carbon dioxide, hydrogen oxide, helium, neon, xenon, krypton, air, oxygen, chlorine, bromine, argon, polyethylene glycol, acetone, ethyl acetate, dimethyl sulfoxide, dimethyl formamide, dioxane, hexamethylphosphorotriamide, perfluorohydrocarbon, methanol, ethanol, tert-butyl alcohol, formic acid, hydrogen fluoride, ammonia, acetic acid, benzene, carbon tetrachloride, acetonitrile, hexane, methylene chloride, carboxylic acid, saline, Ringer's solution, lactated Ringer's solution, Hartmann's solution, acetated Ringer's solution, phosphate buffered solution, TRIS-buffered saline solution, Hank's balanced salt solution, Earle's balanced salt solution, standard saline citrate, HEPES-buffered saline, dextrose, glucose, or diethyl ether. 42. The method of claim 28, wherein the at least one solid frozen particle therapeutic composition includes at least one major dimension of approximately one centimeter or less, approximately one millimeter or less, approximately one micrometer or less, approximately one nanometer or less, or any value therebetween. 43. The method of claim 28, wherein the at least one solid frozen particle therapeutic composition includes one or more reinforcement agents. 44. The method of claim 28, wherein the at least one solid frozen particle therapeutic composition includes one or more explosive agents. 45. The method of claim 28, wherein the receipt by the at least one subject of at least one solid frozen particle therapeutic composition is pursuant to at least one clinical trial. 46. The method of claim 28, further including determining at least one correlation before the administration of the at least one solid frozen particle therapeutic composition. 47. The method of claim 28, further including creating at least one inclusion criterion and at least one exclusion criterion for a clinical trial involving the at least one solid frozen particle therapeutic composition. 48. The method of claim 28, further including suggesting the inclusion of one or more of the at least one subject in at least one clinical trial. 49. The method of claim 28, further including suggesting the exclusion of one or more of the at least one subject in at least one clinical trial. 50. The method of claim 28, further including using one or more of the at least one determination to predict at least one clinical outcome regarding at least one second subject. 51. The method of claim 50, wherein the at least one second subject has not received the at least one solid frozen particle therapeutic composition. 52. The method of claim 50, wherein using one or more of the at least one comparison further includes predicting at least one clinical outcome involving the at least one second subject, wherein the at least one second subject is a plurality of people; and segregating subject identifiers associated with the plurality of people in reference to the predicted at least one clinical outcome. 53. The method of claim 51, further including determining the eligibility of the at least one second subject for at least one clinical trial.

이 특허에 인용된 특허 (173)

Dennis Edward A. (1921 Hypatia Way La Jolla CA 92037-3322). Prodrugs. USP1994105352673.

Meyer Bernard H. (Newtown Square PA) Kinslow Joseph C. (Media PA). Purification, impregnation and foaming of polymer particles with carbon dioxide. USP1991095049328.

St. Clair David J. (Houston TX) Hansen David R. (Houston TX). Radiation cured polydiene based polymer composition. USP1979054152231.

Laugharn ; Jr. James A. ; Bradley David W. ; Hess Robert A.. Rapid cryobaric sterilization and vaccine preparation. USP2001086270723.

Aono Masao (Mishima JPX) Kanaoka Hiroshi (Suita JPX). Refrigerator with an automatic ice maker. USP1992025090208.

Van Meter,Kyle B.; Martin,Dean A.; Fu,Xiaoyong. Refrigerator with intermediate temperature icemaking compartment. USP2007107284390.

Thomas D. Petersen. Scalpel with a double grind blade edge and detachable handle. USP2002126500187.

Ellinwood ; Jr. Everett H. (3519 Tonbridge Way Durham NC 27707). Self-powered implanted programmable medication system and method. USP1979034146029.

Geskin, Ernest S.; Goldenberg, Boris. Selfrechargeable gun and firing procedure. USP2004036705194.

Dietl Josef (Neutting DEX) Holm Claus (Baldham DEX) Sirtl Erhard (Marktl DEX). Semicontinuous process for the manufacture of pure silicon. USP1982014312850.

Indlekofer,Markus. Shot-blasting installation for blasting work pieces made from light metal alloys. USP2008097421872.

Padovani Francois A. (Dallas TX). Silicon seed production process. USP1980064207360.

Medina, Augusto S.; Whigham, Roger; Fisher, John J.; Gann, Barbara; Weinaug, Kenneth S.; Staten, Richard. Simulated frozen beverage composition and method of manufacture thereof. USP2004036712237.

Lee Hyeon-Kook,KRX ; Park Jung-Hwan,KRX ; Choi Nam-Sok,KRX ; Kim Myung-Jin,KRX ; Kim Soo-Hyeon,KRX. Single-shot vaccine formulation. USP1998055753234.

Bruelle Georges (Paris FRX). Sizzling and crunchy chocolate candy. USP1981094289790.

Paul J. Weber ; Luiz B. Da Silva ; Michael R. Weber. Skin decoration apparatus and method. USP2002016341831.

Weber Paul J. ; Weber Michael R. ; Da Silva Luiz B.. Skin resurfacing and treatment using biocompatible materials. USP2001106306119.

Stewart ; Jr. William E. (Olathe KS) Greer Michael E. (Gladstone MO) Dona Carol L. G. (Overland Park KS). Slush ice making system and methods. USP1990034907415.

Nikkanen John P.. Snow maker. USP2000106129290.

Galt John,CAX ; Kestle Martin,CAX ; Yetter James,CAX. Sound insulated injection molding machine. USP1998015707667.

Clauss Steven L. (Manville NJ) Pastel Michael J. (Highland Mills NY) Zawadzki Rainer K. (Wuhan CNX). Stable porfimer sodium compositions and methods for their manufacture. USP1995085438071.

Settles Gary S.. Supersonic abrasive iceblasting apparatus. USP1998075785581.

Goenka Lakhi N. (Ann Arbor MI). Supersonic exhaust nozzle having reduced noise levels for CO₂ cleaning system. USP1995025390450.

Peterson Ronald V. (Thousand Oaks CA) Krone-Schmidt Wilfried (Fullerton CA). System for precision cleaning by jet spray. USP1994055315793.

Boyden, Edward S.; Cook, Daniel B.; Hyde, Roderick A.; Leuthardt, Eric C.; Myhrvold, Nathan P.; Sweeney, Elizabeth A.; Wood, Jr., Lowell L.. Systems, devices, and methods for making or administering frozen particles. USP2012098256233.

Weber, Paul J.; Da Silva, Luiz B.; Rubenchik, Alexander M.. Tissue removal using biocompatible materials. USP2004076764493.

Weber, Paul J.; Da Silva, Luiz B.; Rubenchik, Alexander M.. Tissue resurfacing using biocompatible materials. USP2004046726693.

Hendler Sheldon S. (La Jolla CA) Sanchez Robert (Carlsbad CA). Tocopherol-based antiviral agents and method of using same. USP1992055114957.

Patrin John C. ; Heitzinger John M.. Treating substrates by producing and controlling a cryogenic aerosol. USP1999105961732.

Carter William A.. Treating viral infections associated with chronic fatigue with dsRNA. USP2000106130206.

Akedo,Jun. Ultra fine particle film forming method and apparatus. USP2006016991515.

Van De Wijdeven Giisbertus G. P.,NLX. Use of starch for transdermal applications. USP1999126001385.

Luenemann Brigitte (Alter Fischmarkt 1 D-4400 Munster DEX). Wart treatment. USP1991045006338.

Clark Leland L. (Salt Lake City UT). Wart treatment with phosphonoacetic acid or derivatives thereof. USP1977044016264.

Coleman William P. ; Tsai Ren-Yeu,TWX. Water jet for dermatological treatment. USP2001076264666.

Li Chun ; Wallace Sidney ; Yu Dong-Fang ; Yang David J.. Water soluble paclitaxel prodrugs. USP1999115977163.

Santa Cruz Cathy D. ; Deniston-Korgol Christine L. ; Baugh Barbara I. ; Baugh Alexandria D. ; Baugh Roger D.. Weather-proof wrist, forearm, and elbow protectors. USP2000076092235.

Mellinger Gilbert (Jacksonville FL). Weight loss management system. USP1990084951197.

Dean ; Jr. Robert C. (Norwich VT) Silver Frederick H. (Long Valley NJ) Berg Richard A. (Lambertville NJ) Phillips Philip G. (Norwich VT) Runstadler ; Jr. Peter W. (Hanover NH). Weighted collagen microsponge for immobilizing bioactive material. USP1989084861714.

Hans J. Dysarsz CA; Rhonda Lorraine Millikin CA. Wildlife conditioning and suppression system. USP2002066407670.

Nadicksbernd, Reinhard. Working chamber system and seal device. USP2004056732424.

이 특허를 인용한 특허 피인용횟수: 1

Falo, Jr., Louis D.; Erdos, Geza; Ozdoganlar, O. Burak. Tip-loaded microneedle arrays for transdermal insertion. USP2018049944019.

IPC 상위 출원인

내보내기

상세정보
내보내기 구분	파일저장 인쇄 메일전송
구성항목	관리번호, 국가코드, 자료구분, 상태, 출원번호, 출원일자, 공개번호, 공개일자, 등록번호, 등록일자, 발명명칭(한글), 발명명칭(영문), 출원인(한글), 출원인(영문), 출원인코드, 대표IPC 관리번호, 국가코드, 자료구분, 상태, 출원번호, 출원일자, 공개번호, 공개일자, 공고번호, 공고일자, 등록번호, 등록일자, 발명명칭(한글), 발명명칭(영문), 출원인(한글), 출원인(영문), 출원인코드, 대표출원인, 출원인국적, 출원인주소, 발명자, 발명자E, 발명자코드, 발명자주소, 발명자 우편번호, 발명자국적, 대표IPC, IPC코드, 요약, 미국특허분류, 대리인주소, 대리인코드, 대리인(한글), 대리인(영문), 국제공개일자, 국제공개번호, 국제출원일자, 국제출원번호, 우선권, 우선권주장일, 우선권국가, 우선권출원번호, 원출원일자, 원출원번호, 지정국, Citing Patents, Cited Patents
저장형식	Text(ASCII format) Excel format PIAS분석(.xls)
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	> 총 건의 자료가 검색되었습니다. > 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) > 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. > 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) > 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오 > ~ > Text(ASCII format) Excel format

과학기술 지식인프라 ScienceON

ScienceON Chatbot

연합인증

특허 상세정보

Compositions and methods for therapeutic delivery with frozen particles

초록

대표
청구항
▼

이 특허에 인용된 특허 (173)

이 특허를 인용한 특허 피인용횟수: 1

IPC 상위 출원인

과제정보

상세정보조회

원문조회

IPC 상세정보(version : 201201)

연구과제 성과물(0)

참여연구원의 다른 문헌(0)

처리중입니다.

잠시만 기다려주세요.

ScienceON Chatbot

연합인증

특허 상세정보

Compositions and methods for therapeutic delivery with frozen particles

초록

대표청구항 ▼

이 특허에 인용된 특허 (173)

이 특허를 인용한 특허 피인용횟수: 1

IPC 상위 출원인

과제정보

상세정보조회

원문조회

IPC 상세정보(version : 201201)

연구과제 성과물(0)

참여연구원의 다른 문헌(0)

처리중입니다.

잠시만 기다려주세요.

대표
청구항
▼